Sofinnova Investments’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,194,278
| Closed | -$9.9M | – | 74 |
|
|
2025
Q2 | $9.9M | Hold |
2,194,278
| – | – | 0.61% | 43 |
|
|
2025
Q1 | $9.72M | Hold |
2,194,278
| – | – | 0.63% | 38 |
|
|
2024
Q4 | $17.2M | Hold |
2,194,278
| – | – | 1.25% | 25 |
|
|
2024
Q3 | $28.9M | Hold |
2,194,278
| – | – | 2.29% | 13 |
|
|
2024
Q2 | $26.5M | Hold |
2,194,278
| – | – | 1.38% | 23 |
|
|
2024
Q1 | $35.7M | Hold |
2,194,278
| – | – | 1.99% | 18 |
|
|
2023
Q4 | $15M | Hold |
2,194,278
| – | – | 0.84% | 29 |
|
|
2023
Q3 | $12M | Hold |
2,194,278
| – | – | 0.75% | 34 |
|
|
2023
Q2 | $14.9M | Hold |
2,194,278
| – | – | 0.98% | 26 |
|
|
2023
Q1 | $11M | Hold |
2,194,278
| – | – | 0.7% | 32 |
|
|
2022
Q4 | $10.7M | Hold |
2,194,278
| – | – | 0.64% | 30 |
|
|
2022
Q3 | $31.6M | Hold |
2,194,278
| – | – | 1.84% | 13 |
|
|
2022
Q2 | $33.2M | Hold |
2,194,278
| – | – | 2.76% | 8 |
|
|
2022
Q1 | $26.1M | Hold |
2,194,278
| – | – | 1.98% | 11 |
|
|
2021
Q4 | $35.6M | Hold |
2,194,278
| – | – | 2.08% | 10 |
|
|
2021
Q3 | $62.6M | Hold |
2,194,278
| – | – | 3.71% | 6 |
|
|
2021
Q2 | $74.2M | Hold |
2,194,278
| – | – | 4.27% | 4 |
|
|
2021
Q1 | $66.4M | Hold |
2,194,278
| – | – | 3.99% | 5 |
|
|
2020
Q4 | $109M | Hold |
2,194,278
| – | – | 6.47% | 4 |
|
|
2020
Q3 | $84.2M | Hold |
2,194,278
| – | – | 6.25% | 4 |
|
|
2020
Q2 | $94.8M | Hold |
2,194,278
| – | – | 5.98% | 4 |
|
|
2020
Q1 | $57.3M | Hold |
2,194,278
| – | – | 5.3% | 6 |
|
|
2019
Q4 | $68.6M | Buy |
2,194,278
+90,000
| +4% | +$2.66M | 4.94% | 7 |
|
|
2019
Q3 | $54.8M | Hold |
2,104,278
| – | – | 4.96% | 5 |
|
|
2019
Q2 | $48.1M | Hold |
2,104,278
| – | – | 4.42% | 7 |
|
|
2019
Q1 | $55.2M | Hold |
2,104,278
| – | – | 5.32% | 6 |
|
|
2018
Q4 | $42.8M | Hold |
2,104,278
| – | – | 5.33% | 6 |
|
|
2018
Q3 | $55.9M | Buy |
+2,104,278
| New | +$53.5M | 4.98% | 7 |
|
Other funds holding YMAB
Sofinnova Investments's YMAB Position: Q3 2025 in Review
Sofinnova Investments sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 2,194,278 shares — an estimated $9.9M sold.
Sofinnova Investments first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $109M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Sofinnova Investments reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Sofinnova Investments sold 2,194,278 Y-mAbs Therapeutics shares in Q3 2025, an estimated $9.9M.
- Sofinnova Investments first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- Sofinnova Investments's Y-mAbs Therapeutics position peaked at $109M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.